Leaflet SIMULECT 20mg lyophilisate and solvent for solution for injection / infusion
Product code: W13098001 Quantity: 1
Indicated for: prevention of transplant rejection
Route of administration: injectable / infusion
Substance: basiliximab (monoclonal antibody)
ATC: L04AC02 (Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Basiliximab is a monoclonal antibody used to prevent acute graft rejection in patients who have undergone kidney transplantation. It works by blocking the interleukin-2 receptor (IL-2R) on activated T lymphocytes, thereby inhibiting the immune response that could lead to organ rejection.
Basiliximab is administered intravenously, usually in two doses: the first before transplantation and the second a few days after the procedure. It is used in combination with other immunosuppressive drugs, such as cyclosporine and corticosteroids, to enhance treatment efficacy.
Common side effects include nausea, fever, infections, and injection site reactions. In rare cases, severe allergic reactions or opportunistic infections may occur. Careful monitoring of the patient's condition is essential during treatment.
Basiliximab is an important therapeutic option for kidney transplant patients, helping to reduce the risk of acute rejection and improve long-term outcomes.
General data about SIMULECT 20mg
- Substance: basiliximab
- Date of latest medicines list: 01-08-2023
- Product code: W13098001
- Concentration: 20mg
- Pharmaceutical form: lyophilisate and solvent for solution for injection / infusion
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.